Nektar Therapeutics grants inducement awards to new hires
Nektar Therapeutics granted 20,500 stock options and 3,900 RSUs to seven new employees under its 2025 Inducement Plan, with options priced at $60.98 per share. The awards, approved on June 19, 2026, vest over four years and are subject to continued employment. The plan was adopted in November 2025 to attract new talent.
*this image is generated using AI for illustrative purposes only.
Nektar Therapeutics granted non-qualified stock options to purchase 20,500 shares of common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under its 2025 Inducement Plan. The grants were approved by the Organization and Compensation Committee of Nektar's Board of Directors on June 19, 2026. These awards serve as an inducement material to the individuals entering into employment with the company, pursuant to Nasdaq Listing Rule 5635(c)(4).
The 2025 Inducement Plan was adopted by the Board of Directors on November 6, 2025, and is used exclusively for granting equity awards to individuals who were not previously employees or non-employee directors of Nektar. The stock options carry an exercise price of $60.98 per share, which equals the closing price of Nektar's common stock on June 18, 2026.
Grant Details
The stock options and RSUs are subject to the terms and conditions of the 2025 Inducement Plan and the respective award agreements. The vesting schedules for the awards are structured over a four-year period.
| Award Type | Quantity | Exercise Price | Vesting Term | Vesting Schedule |
|---|---|---|---|---|
| Stock Options | 20,500 shares | $60.98 | 8 years | 25% at 1 year; monthly thereafter for 3 years |
| RSUs | 3,900 units | N/A | 4 years | 25% at 1 year; quarterly thereafter for 3 years |
The stock options have an eight-year term. Vesting for both options and RSUs is contingent upon each employee's continued employment with Nektar on the applicable vesting dates. For stock options, 1/4th of the shares vest on the one-year anniversary of the grant date, with 1/48th vesting monthly thereafter over the next three years. The RSUs follow a similar pattern, with 1/4th vesting after the one-year anniversary and 1/16th vesting quarterly over the subsequent three years.
How will the use of the 2025 Inducement Plan impact Nektar's overall equity dilution and shareholder value over the next four years?
What strategic roles are these newly-hired employees expected to play, and how might their expertise influence Nektar's pipeline development?
Could the $60.98 exercise price signal confidence in future stock performance, or does it reflect current market conditions?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
